Background We assessed the glucose-lowering efficacy of adding empagliflozin versus dose escalating existing medications in patients with uncontrolled type 2 diabetes (T2D).
Methods This was a 6-month retrospective case-control study in subjects with uncontrolled T2D (glycated hemoglobin [HbA1c] >7%) on conventional treatment. The study group started add-on therapy with empagliflozin (10 mg once a day) while the control group was up-titrated with existing medication, using either monotherapy or a combination of metformin, sulfonylurea, and a dipeptidyl peptidase-4 inhibitor. The primary endpoints included changes in HbA1c, fasting plasma glucose (FPG), and 2-hour postprandial glucose (PP2) levels. Secondary outcomes included changes in body composition, body mass index (BMI), and serum ketone bodies, and urinary excretion of sodium, potassium, chlorine, calcium, phosphorus, and glucose.
Results After treatment, the reduction in HbA1c was significantly greater in the empagliflozin group than in controls (from 8.6%±1.6% to 7.6%±1.5% vs. 8.5%±1.1% to 8.1%±1.1%; P<0.01). Similar patterns were found in FPG and PP2 levels. Empagliflozin decreased systolic and diastolic blood pressure, triglycerides, and alanine and aspartate aminotransferase levels. Body weight, BMI, waist circumference, fat mass, and abdominal visceral fat area decreased significantly while lean body mass was maintained. Total ketones, β-hydroxybutyrate, and acetoacetate levels increased significantly after empagliflozin.
Conclusion In addition to glucose lowering, an empagliflozin add-on regimen decreased blood pressure and body fat, and improved metabolic profiles significantly. Empagliflozin add-on is superior to dose escalation in patients with T2D who have inadequate glycemic control on standard medications.
Citations
Citations to this article as recorded by
Independent association of thigh muscle fat density with vascular events in Korean adults Hun Jee Choe, Won Chang, Matthias Blüher, Steven B. Heymsfield, Soo Lim Cardiovascular Diabetology.2024;[Epub] CrossRef
Sodium glucose co-transporter-2 inhibitor, Empagliflozin, is associated with significant reduction in weight, body mass index, fasting glucose, and A1c levels in Type 2 diabetic patients with established coronary heart disease: the SUPER GATE study Satilmis Bilgin, Ozge Kurtkulagi, Tuba Taslamacioglu Duman, Burcin Meryem Atak Tel, Gizem Kahveci, Murat Kiran, Eray Erge, Gulali Aktas Irish Journal of Medical Science (1971 -).2022; 191(4): 1647. CrossRef
A randomized clinical trial evaluating the effect of empagliflozin on triglycerides in obese adults: Role of visceral fat Min Hee Lee, Ian J. Neeland, Natalia de Albuquerque Rocha, Connor Hughes, Craig R. Malloy, Eunsook S. Jin Metabolism Open.2022; 13: 100161. CrossRef
Initial combination of metformin, sitagliptin, and empagliflozin in drug‐naïve patients with type 2 diabetes: Safety and metabolic effects Soo Lim, Minji Sohn, Yujin Shin, Ele Ferrannini Diabetes, Obesity and Metabolism.2022; 24(4): 757. CrossRef
Correlation of dynamic membrane fluctuations in red blood cells with diabetes mellitus and cardiovascular risks Minji Sohn, Ji Eun Lee, MinGeun Ahn, YongKeun Park, Soo Lim Scientific Reports.2021;[Epub] CrossRef
Comparison betweeen dapagliflozin add-on therapy and insulin dose escalation in patients with uncontrolled type 2 diabetes treated with insulin: DVI study Yujin Shin, Haeri Choi, Soo Lim Diabetes Research and Clinical Practice.2021; 175: 108843. CrossRef
Impact of COVID-19 and Associated Preventive Measures on Cardiometabolic Risk Factors in South Korea Minji Sohn, Bo Kyung Koo, Ho Il Yoon, Kyoung-Ho Song, Eu Suk Kim, Hong Bin Kim, Soo Lim Journal of Obesity & Metabolic Syndrome.2021; 30(3): 248. CrossRef